Skip to main content
Erschienen in: Journal of Clinical Monitoring and Computing 6/2022

28.01.2022 | Original Research

Memsorb™, a novel CO2 removal device part I: in vitro performance with the Zeus IE®

verfasst von: Mohammed K. Bashraheel, Sarah A. Eerlings, Andre M. De Wolf, Arne Neyrinck, Marc Van de Velde, Geert Vandenbroucke, Rik Carette, Jeffrey Feldman, Jan F. A. Hendrickx

Erschienen in: Journal of Clinical Monitoring and Computing | Ausgabe 6/2022

Einloggen, um Zugang zu erhalten

Abstract

Soda lime-based CO2 absorbents are safe, but not ideal for reasons of ecology, economy, and dust formation. The Memsorb™ is a novel CO2 removal device that uses cardiopulmonary bypass oxygenator technology instead: a sweep gas passes through semipermeable hollow fibers, adding or removing gas from the circle breathing system. We studied the in vitro performance of a prototype Memsorb™ used with a Zeus IE® anesthesia machine when administering sevoflurane and desflurane in O2/air mixtures. The Zeus IE® equipped with Memsorb™ ventilated a 2L breathing bag with a CO2 inflow port in its tip. CO2 kinetics were studied by using different combinations of CO2 inflow (VCO2), Memsorb™ sweep gas flow, and Zeus IE® fresh gas flow (FGF) and ventilator settings. More specifically, it was determined under what circumstances the inspired CO2 concentration (FICO2) could be kept < 0.5%. O2 kinetics were studied by measuring the inspired O2 concentration (FIO2) resulting from different combinations of Memsorb™ sweep gas flow and O2 concentrations, and Zeus IE® FGFs and O2 concentrations. Memsorb™’s sevoflurane and desflurane waste was determined by measuring their injection rates during target-controlled closed-circuit anesthesia (TCCCA), and were compared to historical controls when using a soda lime absorbent (Draegersorb 800+) under identical conditions. With 160 mL/min VCO2 and 5 L/min minute ventilation (MV), lowering the sweep gas flow at any fixed Zeus IE® FGF increased FICO2 in a non-linear manner. Sweep gas flow adjustments kept FICO2 < 0.5% over the entire Zeus IE® FGF range tested with VCO2 up to 280 mL/min; tidal volume and respiratory rate affected the required sweep gas flow. At 10 L/min MV and low FGF (< 1.5 L/min), even a maximum sweep flow of 43 L/min was unable to keep FICO2 ≤ 0.5%. When the O2 concentration in the Zeus IE® FGF and the Memsorb™ sweep gas flow differed, FIO2 drifted towards the sweep gas O2 concentration, and more so as FGF was lowered; this effect was absent once FGF > minute ventilation. During sevoflurane and desflurane TCCCA, the Zeus IE® FGF remained zero while agent usage per % end-expired agent increased with increasing end-expired target agent concentrations and with a higher target FIO2. Agent waste during target-controlled delivery was higher with Memsorb™ than with the soda lime product, with the difference remaining almost constant over the FGF range studied. With a 5 L/min MV, Memsorb™ successfully removes CO2 with inflow rates up to 240 mL/min if an FICO2 of 0.5% is accepted, but at 10 L/min MV and low FGF (< 1.5 L/min), even a maximum sweep flow of 43 L/min was unable to keep FICO2 ≤ 0.5%. To avoid FIO2 deviating substantially from the O2 concentration in the fresh gas, the O2 concentration in the fresh gas and sweep gas should match. Compared to the use of Ca(OH)2 based CO2 absorbent, inhaled agent waste is increased. The device is most likely to find its use integrated in closed loop systems.
Literatur
2.
Zurück zum Zitat De Cooman S, Lecain A, Sosnowski M, De Wolf AM, Hendrickx JFA. Desflurane consumption with the Zeus® during automated closed circuit versus low flow anesthesia. Acta Anaesthesiol Belg. 2009;60:35–7.PubMed De Cooman S, Lecain A, Sosnowski M, De Wolf AM, Hendrickx JFA. Desflurane consumption with the Zeus® during automated closed circuit versus low flow anesthesia. Acta Anaesthesiol Belg. 2009;60:35–7.PubMed
4.
Zurück zum Zitat Bashraheel MK, Eerlings SA, De Wolf AM, Neyrinck A, Van de Velde M, Vandenbroucke G, Carette R, Feldman J, Hendrickx JFA. Memsorb™, a novel CO2 removal device. Part II: in vivo performance with the Zeus IE®. Bashraheel MK, Eerlings SA, De Wolf AM, Neyrinck A, Van de Velde M, Vandenbroucke G, Carette R, Feldman J, Hendrickx JFA. Memsorb™, a novel CO2 removal device. Part II: in vivo performance with the Zeus IE®.
Metadaten
Titel
Memsorb™, a novel CO2 removal device part I: in vitro performance with the Zeus IE®
verfasst von
Mohammed K. Bashraheel
Sarah A. Eerlings
Andre M. De Wolf
Arne Neyrinck
Marc Van de Velde
Geert Vandenbroucke
Rik Carette
Jeffrey Feldman
Jan F. A. Hendrickx
Publikationsdatum
28.01.2022
Verlag
Springer Netherlands
Erschienen in
Journal of Clinical Monitoring and Computing / Ausgabe 6/2022
Print ISSN: 1387-1307
Elektronische ISSN: 1573-2614
DOI
https://doi.org/10.1007/s10877-021-00802-0

Weitere Artikel der Ausgabe 6/2022

Journal of Clinical Monitoring and Computing 6/2022 Zur Ausgabe

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Ärztliche Empathie hilft gegen Rückenschmerzen

23.04.2024 Leitsymptom Rückenschmerzen Nachrichten

Personen mit chronischen Rückenschmerzen, die von einfühlsamen Ärzten und Ärztinnen betreut werden, berichten über weniger Beschwerden und eine bessere Lebensqualität.

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.